[Chronic hepatitis B in rheumatic diseases: issues of screening and reactivation of infection: A review].
G I GridnevaB S BelovE S AronovaPublished in: Terapevticheskii arkhiv (2024)
Patients with rheumatic diseases infected with hepatitis B virus (HBV) are difficult to manage not only due to the presence of risk factors for the development and rapid progression of liver cirrhosis, but also due to the likelihood of reactivation of this infection. Despite the successes achieved in the fight against HBV, the virus cannot be completely defeated due to the presence of hidden forms of the disease, escaping the field of vision of a rheumatologist and an infectionist. Based on the results of the analysis of current publications, the paper presents the rationale for a complete immunological screening of patients with rheumatic diseases when prescribing antirheumatic therapy. The issues of the role of COVID-19 in the exacerbation of chronic viral hepatitis B, antiviral prevention and monitoring are discussed, the classification of antirheumatic drugs according to the risk of HBV reactivation is presented.
Keyphrases
- hepatitis b virus
- sars cov
- rheumatoid arthritis
- liver failure
- coronavirus disease
- rheumatoid arthritis patients
- primary care
- chronic obstructive pulmonary disease
- machine learning
- deep learning
- clinical trial
- emergency department
- disease activity
- stem cells
- bone marrow
- drug induced
- intensive care unit
- mesenchymal stem cells
- respiratory syndrome coronavirus
- loop mediated isothermal amplification
- liver fibrosis
- mechanical ventilation